Gavocabtagene Autoleucel is a gene-modified cell therapy commercialized by TCR2 Therapeutics, with a leading Phase II program in Malignant Pleural Mesothelioma. According to Globaldata, it is involved in 2 clinical trials, of which 1 is ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Gavocabtagene Autoleucel’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Gavocabtagene Autoleucel is expected to reach an annual total of $111 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Gavocabtagene Autoleucel Overview
TC-210 is under development for the treatment of solid tumors such as ovarian cancer, pancreatic cancer, mesothelioma, cholangiocarcinoma and non-small cell lung cancer. It is administered through the intravenous route. It acts by targeting mesothelin. The drug candidate comprises a lentiviral vector to transfer the genetic information for the TRuC construct into a patient’s own T cells. The therapeutic candidate is developed based on TRuC-T platform technology.
TCR2 Therapeutics Overview
TCR2 Therapeutics is an immuno-oncology company that develops novel therapies for the treatment of various cancers. The company develops a pipeline of TRuC program for solid and hematologic cancers. It also develops TC-210 TRuC-T cell program and CD19-TRuC-T cell program. The company’s TC-210 TRuC-T cell program targets mesothelin-expressing solid tumors including ovarian, pancreatic, lung, mesothelioma, and cholangiocarcinoma. It also develops TRuC variants with other elements which are designed to maintain the immunotherapeutic response. It partners with other pharmaceutical companies and hospitals to develop novel therapies. TCR2 Therapeutics is headquartered in Cambridge, Massachusetts, the US.
The operating loss of the company was US$99.7 million in FY2021, compared to an operating loss of US$68.7 million in FY2020. The net loss of the company was US$99.8 million in FY2021, compared to a net loss of US$67.1 million in FY2020.
For a complete picture of Gavocabtagene Autoleucel’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.